Merck and Immune Design to assess two immunotherapies with Keytruda for NHL and Melanoma

Clinical-stage immunotherapy firm Immune Design has partnered with the subsidiaries of Merck to assess the safety and efficacy of its oncology investigative agents, G100 and LV305, with Merck's Keytruda (pembrolizumab) for non-Hodgkin's lymphoma (NHL…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news